|
|
| (38 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__ | | __NOTOC__ |
| {{CMG}}; {{AE}} {{AK}} | | {{CMG}};{{AE}}{{AK}} |
| | | ==Definition== |
| ==Definition== | | COPD exacerbation commonly caused by infections, should be recognized when any of the following symptoms is noticed in a chronic COPD patient:worsening cough, increasing dyspnea, increasing in sputum production more than the baseline for chronic COPD patients.<ref name="pmid17507545">{{cite journal| author=Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P et al.| title=Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. | journal=Am J Respir Crit Care Med | year= 2007 | volume= 176 |issue= 6 | pages= 532-55 | pmid=17507545 | doi=10.1164/rccm.200703-456SO | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17507545 }} </ref> |
| * Exacerbation of COPD is an acute event characterized by a worsening of the patient’s respiratory symptoms that is beyond normal day-to-day variations and leads to a change in medication.<ref name="Burge-2003">{{Cite journal | last1 = Burge | first1 = S. | last2 = Wedzicha | first2 = JA. | title = COPD exacerbations: definitions and classifications. | journal = Eur Respir J Suppl | volume = 41 | issue = | pages = 46s-53s | month = Jun | year = 2003 | doi = | PMID = 12795331 }}</ref><ref name="Celli-2007">{{Cite journal | last1 = Celli | first1 = BR. | last2 = Barnes | first2 = PJ. | title = Exacerbations of chronic obstructive pulmonary disease. | journal = Eur Respir J | volume = 29 | issue = 6 | pages = 1224-38 | month = Jun | year = 2007 | doi = 10.1183/09031936.00109906 | PMID = 17540785 }}</ref><ref name="Rodriguez-Roisin-2000">{{Cite journal | last1 = Rodriguez-Roisin | first1 = R. | title = Toward a consensus definition for COPD exacerbations. | journal = Chest | volume = 117 | issue = 5 Suppl 2 | pages = 398S-401S | month = May | year = 2000 | doi = | PMID = 10843984 }}</ref>
| |
| | |
| * The diagnosis of an exacerbation relies exclusively on the clinical presentation of the patient complaining of an acute change of symptoms ('''baseline dyspnea, cough, and/or sputum production''') that is beyond normal day-to-day variation.<ref name="Vestbo-2013">{{Cite journal | last1 = Vestbo | first1 = J. | last2 = Hurd | first2 = SS. | last3 = Agustí | first3 = AG. | last4 = Jones | first4 = PW. | last5 = Vogelmeier | first5 = C. | last6 = Anzueto | first6 = A. | last7 = Barnes | first7 = PJ. | last8 = Fabbri | first8 = LM. | last9 = Martinez | first9 = FJ. | title = Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. | journal = Am J Respir Crit Care Med | volume = 187 | issue = 4 | pages = 347-65 | month = Feb | year = 2013 | doi = 10.1164/rccm.201204-0596PP | PMID = 22878278 }}</ref>
| |
|
| |
|
| ==Causes== | | ==Causes== |
| ===Life-Threatening Causes=== | | ===Life Threatening Causes=== |
| <SMALL>''Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.''</SMALL>
| | Include conditions which may result death or permanent disability within 24 hours if left untreated, and some of them may mimic and/or aggravate exacerbations: |
| * [[Arrhythmia]] | | *[[Pneumonia]] |
| * [[Congestive heart failure]] | | *[[PE]] |
| * [[Pleural effusion]] | | *[[Pneumothorax]] |
| * [[Pneumonia]] | | *[[Pleural effusion]] |
| * [[Pneumothorax]] | | *[[CHF]] |
| * [[Pulmonary embolism]] | | *[[Cardiac arrhythmias]] |
|
| |
|
| ===Common Causes=== | | ===Common Causes=== |
| * [[Respiratory tract infections]] (~½) | | *Respiratory tract infections 50%(bacterial or viral). |
| * Unknown (~⅓) | | *Exposure to pollutants. |
| * Air pollutants
| | *Unknown (⅓ of cases ). |
|
| |
|
| ==Treatment Setting and Severity== | | ==Differential Diagnosis== |
| {{Family tree/start}}
| | * [[Asthma]] |
| {{Family tree |border=2|boxstyle=background: WhiteSmoke;|A1|A1=<div style="float: left; text-align: left; height: 5.5em; width: 9.7em; padding: 1em;">'''COPD Exacerbation''' <BR> ❑ Cough ↑ <BR> ❑ Dyspnea ↑ <BR> ❑ Sputum ↑ </div>}}
| | * [[CHF]] |
| {{Family tree |!|}}
| | * [[PE]] |
| {{Family tree |border=2|boxstyle=background:WhiteSmoke;|)|B1|B1=<div style="float: left; text-align: left; height: 4.8em; width: 41em; padding: 1em">
| | * [[ACS]] |
| '''1. Oxygen Supplement''' <BR> ❑ Pulse oximetry (maintain Sa<sub>O<sub>2</sub></sub> ≥88—92%)<ref name="Austin-2010">{{Cite journal | last1 = Austin | first1 = MA. | last2 = Wills | first2 = KE. | last3 = Blizzard | first3 = L. | last4 = Walters | first4 = EH. | last5 = Wood-Baker | first5 = R. | title = Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. | journal = BMJ | volume = 341 | issue = | pages = c5462 | month = | year = 2010 | doi = | PMID = 20959284 }}</ref> <BR> ❑ Arterial blood gas (if acute or acute-on-chronic respiratory failure is suspected)</div>}}
| | * [[Pneumothorax]] |
| {{Family tree |!|}}
| | * [[Pneumonia]] |
| {{Family tree |border=2|boxstyle=background:WhiteSmoke;|)|C1|C1=<div style="float: left; text-align: left; height: 7em; width: 39em; padding: 1em">
| | * [[Atelectasis|Lobar atelectasis]] |
| '''2. Indications for ICU Admission'''<BR> ❑ Hemodynamic instability <BR> ❑ Changes in mental status (confusion, lethargy, coma) <BR> ❑ Severe dyspnea that responds inadequately to initial emergency therapy <BR> ❑ Worsening hypoxemia (Pa<sub>O<sub>2</sub></sub> <40 mm Hg) and/or respiratory acidosis (pH <7.25)</div>}}
| |
| {{Family tree |!| | |!|}}
| |
| {{Family tree |border=2|boxstyle=background:WhiteSmoke;|!| |D1|D1=<div style="float: left; text-align: left; height: 23em; width: 40em; padding: 1em">'''2a. Indications for Noninvasive Mechanical Ventilation''' <BR> ❑ Respiratory acidosis (arterial pH < 7.35 or Pa<sub>CO<sub>2</sub></sub> >45 mm Hg) <BR> ❑ Severe dyspnea with sings of respiratory muscle fatigue <BR> ❑ Increased work of breathing
| |
| ----
| |
| '''2b. Indications for Invasive Mechanical Ventilation''' <BR> ❑ Diminished consciousness, psychomotor agitation inadequately controlled by sedation <BR> ❑ Severe hemodynamic instability without response to fluids and vasoactive drugs <BR> ❑ Respiratory pauses with loss of consciousness or gasping for air <BR> ❑ Life-threatening hypoxemia in patients unable to tolerate NIV <BR> ❑ Persistent inability to remove respiratory secretions <BR> ❑ Heart rate <50/min with loss of alertness <BR> ❑ Unable to tolerate NIV or NIV failure <BR> ❑ Severe ventricular arrhythmias <BR> ❑ Respiratory or cardiac arrest <BR> ❑ Massive aspiration</div>}}
| |
| {{Family tree |!|}}
| |
| {{Family tree |border=2|boxstyle=background:WhiteSmoke;|`|E1|E1=<div style="float: left; text-align: left; height: 23em; width: 41em; padding: 1em">
| |
| '''3. Indications for Hospitalization''' <BR> ❑ Marked increase in intensity of symptoms (eg, sudden development of resting dyspnea) <BR> ❑ Presence of serious comorbidities (eg, heart failure or newly occurring arrhythmias) <BR> ❑ Failure of an exacerbation to respond to initial medical management <BR> ❑ Onset of new physical signs (eg, cyanosis, peripheral edema) <BR> ❑ Severe underlying COPD (GOLD 3—4 categories) <BR> ❑ Frequent exacerbations (≥2 events per year) <BR> ❑ Insufficient home support <BR> ❑ Older age (>65 years)
| |
| ----
| |
| '''4. Assessment of Severity of Exacerbation''' <BR> ❑ Sputum purulence <BR> ❑ ECG (identify coexisting cardiac problems) <BR> ❑ Chest radiograph (exclude alternative diagnoses) <BR> ❑ Whole-blood count (identify polycythemia, anemia, or leukocytosis) <BR> ❑ Electrolytes and glucose (identify electrolyte disturbances or hyperglycemia)</div>}}
| |
| {{Family tree | | | |!|}}
| |
| {{Family tree |border=2|boxstyle=background:WhiteSmoke;| | | |F1|F1=<div style="float: left; text-align: left; height: 30em; width: 30em; padding: 1em">
| |
| '''Severe Exacerbation''' <BR> ❑ Consider inpatient management <BR> ❑ Assess symptoms, ABG, and CXR <BR> ❑ Monitor fluid balance and nutrition <BR> ❑ Identify and treat associated conditions <BR> ❑ Consider subcutaneous heparin or LMWH <BR> ❑ Controlled oxygen therapy (use NIV if indicated) <BR> ❑ Antibiotics (if ↑ sputum purulence or ⊕ bacterial infection) <BR> ❑ Corticosteroids <BR> ❑ Bronchodilators <BR> ▸ Increase doses/frequency of short-acting bronchodilators <BR> ▸ Combine short-acting β2-agonists and anticholinergics <BR> ▸ Use spacers or air-driven nebulizers
| |
| ----
| |
| '''Moderate Exacerbation''' <BR> ❑ Consider outpatient management <BR> ❑ Require a short course of antibiotics or oral corticosteroids
| |
| ----
| |
| '''Mild Exacerbation''' <BR> ❑ Consider outpatient management <BR> ❑ Require change of inhaled treatment by the patient</div>}}
| |
| {{Family tree/end}}
| |
|
| |
|
| ==Management== | | ==Management== |
|
| |
|
| |
| <!--
| |
| {{Family tree/start}} | | {{Family tree/start}} |
| {{Family tree | | | | A01 | | | |A01= '''COPD Exacerbation'''<br>↑[[cough]], ↑[[dyspnea]], ↑[[sputum]], <br> ↑[[wheezing]], [[fever]] or chest tightness}} | | {{Family tree | | | | A01 | | | |A01= '''COPD Exacerbation'''<br>↑[[cough]], ↑[[dyspnea]], ↑[[sputum]], <br> ↑[[wheezing]], [[fever]] or chest tightness}} |
| Line 60: |
Line 36: |
| {{Family tree | | | | C01 |~| C02 | |C01='''Assessment''' :<br>1-O2 sat+ ABG <br>2-[[CXR]] <br>3-[[EKG]] <br>4-[[CBC]] | | {{Family tree | | | | C01 |~| C02 | |C01='''Assessment''' :<br>1-O2 sat+ ABG <br>2-[[CXR]] <br>3-[[EKG]] <br>4-[[CBC]] |
| <br> | | <br> |
| '''Management:''' <br>1-Inhaled bronchodilators <br>2-Systemic corticosteroids <br>3-Empirical antibiotics <br>4-O2 (target Sat >90%)|C02='''Corticosteroids(Solumedrol)'''<br>Methylprednisolone 125 mg×1 dose <br> followed with 60-80 mg Q8-12based on severity <br> IV Solumedrol to PO Prednisone taper 4--60 mg Q 8-12<br> 2-5 days taper depending on severity<br> '''Antibiotics'''<br>'''Group A'''*<br>Doxycycline Cap '''Vibramycin''' PO 100 mg Q12H<br>(if unable to tolerate choose Cefpodoxime Tab '''Vantin''' PO 200 mg Q12H)<br>'''Group B'''*<br>Ceftriaxone Inj '''Rocephin''' 1GM D5W50 ml Q24H 200 ml/Hr<br>(If Beta-Lactam allergy choose Levofloxacin Tab '''Levaquin''' PO 500 mg daily )<br> '''Group C'''*<br>Ciprofloxacin Tab '''Cipro'''PO 250 Daily<br>or Ciprofloxacin Inj Cipro 400 mg premixed at 400 mg /200 ml Q12H 200 ml/Hr. | | '''Management:''' <br>1-Inhaled bronchodilators <br>2-Systemic corticosteroids <br>3-Empirical antibiotics <br>4-O2 (target Sat >90%)| C02='''Corticosteroids(Solumedrol)'''<br>Methylprednisolone 125 mg×1 dose <br> followed with 60-80 mg Q8-12based on severity <br> IV Solumedrol to PO Prednisone taper 4--60 mg Q 8-12<br> 2-5 days taper depending on severity<br> '''Antibiotics'''<br>'''Group A'''*<br>Doxycycline Cap '''Vibramycin''' PO 100 mg Q12H<br>(if unable to tolerate choose Cefpodoxime Tab '''Vantin''' PO 200 mg Q12H)<br>'''Group B'''*<br>Ceftriaxone Inj '''Rocephin''' 1GM D5W50 ml Q24H 200 ml/Hr<br>(If Beta-Lactam allergy choose Levofloxacin Tab '''Levaquin''' PO 500 mg daily )<br> '''Group C'''*<br>Ciprofloxacin Tab '''Cipro'''PO 250 Daily <br>or Ciprofloxacin Inj Cipro 400 mg premixed at 400 mg /200 ml Q12H 200 ml/Hr. |
| }} | | }} |
| {{Family tree | | | | |!| | | | |}} | | {{Family tree | | | | |!| | | | |}} |
| {{Family tree | | | | D01 | | | |D01=Respiratory acidosis? OR <br> PH≤35? OR<br> PaCo2≥45? OR<br> Severe signs of dyspnea? OR <br>Accessory muscles use,<br>paradoxical motion of abdomen,<br> retraction of intercostal space}} | | {{Family tree | | | | D01 | | | |D01=Respiratory acidosis? OR <br> PH≤35? OR<br> PaCo2≥45? OR<br> Severe signs of dyspnea? OR <br>Accessory muscles use, <br>paradoxical motion of abdomen,<br> retraction of intercostal space}} |
| {{Family tree | | |,|-|^|-|.| | }} | | {{Family tree | | |,|-|^|-|.| | }} |
| {{Family tree | E01 | | | E02 |E01=No | E02= Yes}} | | {{Family tree | E01 | | | E02 |E01=No | E02= Yes}} |
| {{Family tree | |!| | | | |!| |}} | | {{Family tree | |!| | | | |!| |}} |
| {{Family tree | F01 | | | F02|F01=Continue the same management |F02='''ICU Admission''' }} | | {{Family tree | F01 | | | F02|F01=Continue the same management |F02='''ICU Admission''' <br>'''NIV''' }} |
| {{family tree | | | | | | |!| | | | | | |}}
| | {{Family tree | | | | | | |!| |}} |
| {{family tree | | | | | | Z01 | | | | | |Z01=Non-invasive ventilation}}
| |
| {{Family tree | | | | | | |!| | |}} | |
| {{Family tree | | | | | | G01 |G01= Unable to tolerate NIV?<br> Severe hemodynamic instability?<br>Resp/cardiac arrest ? }} | | {{Family tree | | | | | | G01 |G01= Unable to tolerate NIV?<br> Severe hemodynamic instability?<br>Resp/cardiac arrest ? }} |
| {{Family tree | | | | | | |!| | |}} | | {{Family tree | | | | | | |!| | |}} |
| {{Family tree | | | | | | H01 | |H01=Invasive mechanical ventilation}} | | {{Family tree | | | | | | H01 | |H01=Invasive mechanical ventilation}} |
| {{Family tree/end}} | | {{Family tree/end}} |
| -->
| |
|
| |
|
| ==Do's==
| |
| ===Assessment===
| |
| * The presence of purulent sputum during an exacerbation can be sufficient indication for starting empirical antibiotic treatment.<ref name="Stockley-2000">{{Cite journal | last1 = Stockley | first1 = RA. | last2 = O'Brien | first2 = C. | last3 = Pye | first3 = A. | last4 = Hill | first4 = SL. | title = Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. | journal = Chest | volume = 117 | issue = 6 | pages = 1638-45 | month = Jun | year = 2000 | doi = | PMID = 10858396 }}</ref>
| |
|
| |
|
| ===Treatment===
| | '''*Group A''':mild exacerbation, no risk factors, 2>symptoms present |
| =====Treatment Setting=====
| | '''Group B''':Mod Exacerbation w/risk factors for poor outcomes:comorbid disease, severe COPD, Frequent exacerbation>3, Antimicrobial use within the last 3 months |
| * When a patient comes to the ED, the first actions are to provide controlled oxygen therapy and to determine whether the exacerbation is life threatening. If so, the patient should be admitted to the ICU immediately.<ref name="Vestbo-2013">{{Cite journal | last1 = Vestbo | first1 = J. | last2 = Hurd|first2 = SS. | last3 = Agustí |first3 = AG. | last4 = Jones | first4 = PW. | last5 = Vogelmeier | first5 = C. | last6 = Anzueto | first6 = A. | last7 = Barnes | first7 = PJ. | last8 = Fabbri | first8 = LM. | last9 = Martinez | first9 = FJ. | title = Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. | journal = Am J Respir Crit Care Med | volume = 187 | issue = 4 | pages = 347-65 | month = Feb | year = 2013 | doi = 10.1164/rccm.201204-0596PP | PMID = 22878278}}</ref> | | '''Group C''':Severe exacerbation w/risk factors for P.aeruginosa infection. |
|
| |
|
| =====Short-Acting Bronchodilators===== | | ==Do's== |
| * Short-acting inhaled [[Beta2-adrenergic receptor agonist|β2-agonists]] with or without short-acting [[anticholinergic]]s are usually the preferred [[bronchodilator]]s for treatment of an exacerbation.<ref name="Celli-2004">{{Cite journal | last1 = Celli | first1 = BR. | last2 = MacNee | first2 = W. | title = Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. | journal = Eur Respir J | volume = 23 | issue = 6 | pages = 932-46 | month = Jun | year = 2004 | doi = | PMID = 15219010 }}</ref> | | *Monitor fluid balance,nutrition and patient condition closely. |
| | | *Consider subcutaneous heparin or low molecular weight heparin. |
| * A systematic review found no significant differences in [[FEV1|FEV<sub>1</sub>]] between [[Metered-dose inhaler|MDI]] and [[Nebulizer|nebulizers]],<ref name="Turner-">{{Cite journal | last1 = Turner | first1 = MO. | last2 = Patel | first2 = A. | last3 = Ginsburg | first3 = S. | last4 = FitzGerald | first4 = JM. | title = Bronchodilator delivery in acute airflow obstruction. A meta-analysis. | journal = Arch Intern Med | volume = 157 | issue = 15 | pages = 1736-44 | month = | year = | doi = | PMID = 9250235 }}</ref> although the latter can be more convenient for sicker or frail patients. | | *Treat associated conditions if exist(e.g., heart failure,arrhythmias). |
| | |
| * Intravenous [[methylxanthine]]s ([[theophylline]] or [[aminophylline]]) are only to be used in selected cases when there is insufficient response to [[SABA|short-acting bronchodilators]].<ref name="Barberá-1992">{{Cite journal | last1 = Barberá | first1 = JA. | last2 = Reyes | first2 = A. | last3 = Roca | first3 = J. | last4 = Montserrat | first4 = JM. | last5 = Wagner | first5 = PD. | last6 = Rodríguez-Roisin | first6 = R. | title = Effect of intravenously administered aminophylline on ventilation/perfusion inequality during recovery from exacerbations of chronic obstructive pulmonary disease. | journal = Am Rev Respir Dis | volume = 145 | issue = 6 | pages = 1328-33 | month = Jun | year = 1992 | doi = 10.1164/ajrccm/145.6.1328 | PMID = 1595998 }}</ref><ref name="Emerman-1990">{{Cite journal | last1 = Emerman | first1 = CL. | last2 = Connors | first2 = AF. | last3 = Lukens | first3 = TW. | last4 = May | first4 = ME. | last5 = Effron | first5 = D. | title = Theophylline concentrations in patients with acute exacerbation of COPD. | journal = Am J Emerg Med | volume = 8 | issue = 4 | pages = 289-92 | month = Jul | year = 1990 | doi = | PMID = 2363749 }}</ref><ref name="Lloberes-1988">{{Cite journal | last1 = Lloberes | first1 = P. | last2 = Ramis | first2 = L. | last3 = Montserrat | first3 = JM. | last4 = Serra | first4 = J. | last5 = Campistol | first5 = J. | last6 = Picado | first6 = C. | last7 = Agusti-Vidal | first7 = A. | title = Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease. | journal = Eur Respir J | volume = 1 | issue = 6 | pages = 536-9 | month = Jun | year = 1988 | doi = | PMID = 2971565 }}</ref><ref name="Mahon-1999">{{Cite journal | last1 = Mahon | first1 = JL. | last2 = Laupacis | first2 = A. | last3 = Hodder | first3 = RV. | last4 = McKim | first4 = DA. | last5 = Paterson | first5 = NA. | last6 = Wood | first6 = TE. | last7 = Donner | first7 = A. | title = Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice. | journal = Chest | volume = 115 | issue = 1 | pages = 38-48 | month = Jan | year = 1999 | doi = | PMID = 9925061 }}</ref><ref name="Murciano-1984">{{Cite journal | last1 = Murciano | first1 = D. | last2 = Aubier | first2 = M. | last3 = Lecocguic | first3 = Y. | last4 = Pariente | first4 = R. | title = Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease. | journal = N Engl J Med | volume = 311 | issue = 6 | pages = 349-53 | month = Aug | year = 1984 | doi = 10.1056/NEJM198408093110601 | PMID = 6738652 }}</ref> | |
| | |
| =====Corticosteroids=====
| |
| * Systemic corticosteroids in COPD exacerbations shorten recovery time, improve FEV1 and PaO2,<ref name="Davies-1999">{{Cite journal | last1 = Davies | first1 = L. | last2 = Angus | first2 = RM. | last3 = Calverley | first3 = PM. | title = Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. | journal = Lancet | volume = 354 | issue = 9177 | pages = 456-60 | month = Aug | year = 1999 | doi = | PMID = 10465169 }}</ref><ref name="Maltais-2002">{{Cite journal | last1 = Maltais | first1 = F. | last2 = Ostinelli | first2 = J. | last3 = Bourbeau | first3 = J. | last4 = Tonnel | first4 = AB. | last5 = Jacquemet | first5 = N. | last6 = Haddon | first6 = J. | last7 = Rouleau | first7 = M. | last8 = Boukhana | first8 = M. | last9 = Martinot | first9 = JB. | title = Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. | journal = Am J Respir Crit Care Med | volume = 165 | issue = 5 | pages = 698-703 | month = Mar | year = 2002 | doi = 10.1164/ajrccm.165.5.2109093 | PMID = 11874817 }}</ref><ref name="Niewoehner-1999">{{Cite journal | last1 = Niewoehner | first1 = DE. | last2 = Erbland | first2 = ML. | last3 = Deupree | first3 = RH. | last4 = Collins | first4 = D. |last5 = Gross | first5 = NJ. | last6 = Light | first6 = RW. | last7 = Anderson | first7 = P. | last8 = Morgan | first8 = NA. | title = Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. | journal = N Engl J Med | volume = 340 | issue = 25 | pages = 1941-7| month = Jun | year = 1999 | doi = 10.1056/NEJM199906243402502 | PMID = 10379017 }}</ref><ref name="Thompson-1996">{{Cite journal | last1 = Thompson | first1 = WH. | last2 = Nielson | first2 = CP. | last3 = Carvalho | first3 = P. | last4 = Charan | first4 = NB. | last5 = Crowley | first5 = JJ. | title = Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. | journal = Am J Respir Crit Care Med | volume = 154 | issue = 2 Pt 1 | pages = 407-12 | month = Aug | year = 1996 | doi = 10.1164/ajrccm.154.2.8756814 | PMID = 8756814 }}</ref> and reduce the risk of early relapse, treatment failure, and length of hospital stay.<ref name="Davies-1999">{{Cite journal | last1 = Davies | first1 = L. | last2 = Angus | first2 = RM. | last3 = Calverley | first3 = PM. | title = Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. | journal = Lancet | volume = 354 | issue = 9177 | pages = 456-60 | month = Aug | year = 1999 | doi = | PMID = 10465169 }}</ref><ref name="Niewoehner-1999">{{Cite journal | last1 = Niewoehner | first1 = DE. | last2 = Erbland | first2 = ML. | last3 = Deupree | first3 = RH. | last4 = Collins | first4 = D. | last5 = Gross | first5 = NJ. | last6 = Light | first6 = RW. | last7 = Anderson | first7 = P. | last8 = Morgan| first8 = NA. | title = Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. |journal = N Engl J Med | volume = 340 | issue = 25 | pages = 1941-7 | month = Jun | year = 1999 | doi = 10.1056/NEJM199906243402502 | PMID = 10379017 }}</ref><ref name="Aaron-2003">{{Cite journal | last1 = Aaron | first1 = SD. | last2 = Vandemheen | first2 = KL. | last3 = Hebert | first3 = P. | last4 = Dales | first4 = R. | last5 = Stiell | first5 = IG. |last6 = Ahuja | first6 = J. | last7 = Dickinson | first7 = G. | last8 = Brison | first8 = R. | last9 = Rowe | first9 = BH. | title = Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. | journal = N Engl J Med | volume = 348 | issue = 26 | pages = 2618-25 | month = Jun | year = 2003 | doi = 10.1056/NEJMoa023161 |PMID = 12826636 }}</ref>
| |
| | |
| =====Antibiotics=====
| |
| * [[Haemophilus influenzae]], [[Streptococcus pneumoniae]], and [[Moraxella catarrhalis]] are the most common bacterial pathogens involved in an exacerbation.<ref name="Sethi-2008">{{Cite journal | last1 = Sethi | first1 = S. | last2 = Murphy | first2 = TF. | title = Infection in the pathogenesis and course of chronic obstructive pulmonary disease. | journal = N Engl J Med | volume = 359 | issue = 22 | pages = 2355-65 | month = Nov | year = 2008 | doi = 10.1056/NEJMra0800353 | PMID = 19038881 }}</ref> However, the choice of the antibiotic should be based on the local bacterial resistance pattern.
| |
| | |
| * Empirical coverage of [[Pseudomonas aeruginosa]] in GOLD 3 and GOLD 4 patients is important.<ref name="Vestbo-2013">{{Cite journal | last1 = Vestbo | first1 = J. | last2 = Hurd |first2 = SS. | last3 = Agustí |first3 = AG. | last4 = Jones | first4 = PW. | last5 = Vogelmeier | first5 = C. | last6 = Anzueto | first6 = A. | last7 = Barnes | first7 = PJ. | last8 = Fabbri | first8 = LM. | last9 = Martinez | first9 = FJ. | title = Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. | journal = Am J Respir Crit Care Med | volume = 187 | issue = 4 | pages = 347-65 | month = Feb | year = 2013 | doi = 10.1164/rccm.201204-0596PP | PMID = 22878278}}</ref>
| |
| | |
| * [[Procalcitonin]] may be of value in the decision to use antibiotics.<ref name="Christ-Crain-2004">{{Cite journal | last1 = Christ-Crain | first1 = M. | last2 = Jaccard-Stolz | first2 = D. | last3 = Bingisser | first3 = R. | last4 = Gencay | first4 = MM. | last5 = Huber | first5 = PR. | last6 = Tamm | first6 = M. | last7 = Müller | first7 = B. | title = Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. | journal = Lancet | volume = 363 | issue = 9409 | pages = 600-7 | month = Feb | year = 2004 | doi = 10.1016/S0140-6736(04)15591-8 | PMID = 14987884 }}</ref>
| |
| =====Adjunct Therapies=====
| |
| * An appropriate fluid balance with special attention to the administration of diuretics, anticoagulants, treatment of comorbidities, and nutritional aspects should be considered.
| |
| | |
| * At all times, health care providers should strongly enforce stringent measures against active cigarette smoking.
| |
| | |
| ==Don'ts==
| |
| ===Assessment===
| |
| * Spirometry is '''not''' recommended during an exacerbation because it can be difficult to perform and measurements are not accurate enough.
| |
|
| |
|
| ==References== | | ==References== |
| {{Reflist|2}} | | {{reflist|2}} |
| | |
| [[Category:Resident survival guide]]
| |